Latest News

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

Source link

Related posts

Immuno-PET precisely diagnoses IBD inflammation without invasive procedures

Newsemia

Substantial increase in body weight since 1960s due to interplay between genes and environment

Newsemia

Karuna: A New Animal Rescue Community In Town

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World